Ovid Therapeutics is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with deep unmet need. Ovid is developing a pipeline of potential small molecule medicines that seek to meaningfully improve the lives of those affected by diseases of the central nervous system. Ovid’s pipeline of programs includes:
OV329, a next-generation GABA aminotransferase inhibitor, OV350 and library of KCC2 direct activators, and OV888/ GV101 and ROCK2 inhibitor programs.
OV329 seeks to reduce neuronal hyperexcitability with less sedation and without ocular changes that are associated with an older drug in the class, vigabatrin. Ovid's preclinical characterization suggests that OV329 is more potent, delivers synaptic and extra synaptic inhibition, and has a lasting pharmacodynamic effect with rapid tissue clearance. OV329 is currently advancing in a Phase 1 trial, with topline data expected in 2025.
OV350 is the first program from Ovid's library of KCC2 direct activators. Ovid expects to submit a regulatory application for a Phase 1 trial of OV350 before year end 2024, and to initiate in Q1 2025. In preclinical and animal disease models, OV350 has demonstrated anti-psychotic and anticonvulsant effects, indicating it may have broad therapeutic utility.
Ovid is also progressing its KCC2 library, which comprises multiple compounds with different pharmacology and combinations of effects across neurological conditions with high unmet need including, neuropsychiatric, neurodevelopmental, and neurodegenerative applications. These compounds have unique therapeutic characteristics and are amenable for oral and intramuscular formulations to address clinical indications across the care continuum.
Following recent results from competitor trials in CCM, and after discussions with key stakeholders, Ovid and Graviton Bioscience have decided to pause the initiation of the Phase 2 proof-of-concept study of OV888/GV101 capsule in CCM. Ovid and Graviton continue to pursue additional formulations of OV888/ GV101 for undisclosed cerebral vascular conditions with high unmet need.
Ovid is led by a veteran team whose collective experience has contributed to the development and commercialization of more than 25 medicines for neurological and rare diseases in the last two decades.